Dianthus Therapeutics
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 4.76B | -20.72 | 3.84 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 34.2% below Morningstar's fair value estimate.
Fair value
Dianthus Therapeutics Inc earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 19% discount to our quantitative fair value estimate of $113.44 per share; however, caution is warranted due to this estimate's high uncertainty rating.
We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.
Economic moat
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:59:44 · For reference only, not investment advice and not tailored to your situation.
Dianthus Therapeutics discussion 0 comments